Data investigation

Losing Weight Predicted More Heart Attacks

A prespecified analysis of 17,604 people found semaglutide's cardiovascular protection largely independent of weight lost. In the placebo arm, losing weight predicted more cardiac events.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·1 citation

A prespecified analysis of 17,604 people in the SELECT trial asked whether semaglutide’s protection against heart attacks came from the weight it removed. The answer was mostly no.[1] And in the placebo group, the same analysis found that losing weight was associated with more cardiovascular events. That second finding is the more instructive of the two.

The benefit did not follow the weight

Everyone in SELECT was at least 45, carried a BMI of 27 or more, and had heart disease already diagnosed; none had diabetes. Across 41 countries, half drew weekly semaglutide at 2.4 mg and half a placebo. This analysis looked inside that result to ask what the protection tracked.

  • Benefit appeared across every baseline category of body weight and waist circumference. Heavier and lighter participants gained similarly.
  • Weight lost by week 20 showed no linear relationship to heart attacks and strokes afterward.
  • Waist reduction did track it, both at week 20 and over 104 weeks.
  • An estimated 33% of the benefit was mediated through waist reduction (hazard ratio 0.86, 95% CI 0.77–0.97 after adjusting for changes over time).

The authors’ own interpretation is that the cardioprotective effect was independent of baseline adiposity and of weight loss, with only a small association with waist circumference. That points to mechanisms beyond fat reduction. A model that projected a 22% cut in heart risk for people who have never had heart disease rests on the opposite assumption, routing the whole benefit through five risk factors.

Two-thirds of the heart benefit is not explained by anything the scale or the tape measure recorded.

That waist matters while weight does not is itself informative. Waist circumference tracks visceral fat (the metabolically active fat around the organs), while body weight lumps that together with muscle, bone and water. Two people losing the same weight can lose very different tissue, which is a recurring theme in this drug class.

We reached a similar conclusion from a much weaker analysis, a post-hoc mediation study in sleep apnea, in is it just the weight loss. SELECT answers the same question with a prespecified analysis, in 17,604 people, against a hard endpoint.

The sentence in the placebo column

Among people taking placebo, weight loss was paradoxically associated with increased cardiovascular risk. That is worse than neutral, and it was measured the same way, over the same period, as in the semaglutide arm, where weight loss was harmless or helpful.

The likeliest explanation is a familiar one. When no drug is causing it, weight loss is often a sign of illness: developing cancer, heart failure, or the general decline that can precede a cardiac event. In that case weight falls because something is wrong. The weight loss is a symptom, and the cardiac event follows for the same underlying reason.

Epidemiologists call this reverse causation, and it is why decades of observational studies linking weight loss to worse outcomes were so hard to interpret. This instance stands out because of where it appeared: inside a randomized controlled trial, in the control arm, where it cannot be waved away as a defect of observational data.

Put the two arms side by side. The trial, the outcome and the measurement are the same. In one arm, weight coming off is a drug working and carries no extra risk. In the other, weight coming off is a body failing and predicts harm. A change on the scale cannot be read without knowing why it happened.

The lesson applies beyond this trial. Any study that reports weight change as an outcome or a predictor, without establishing what caused it, is reporting an ambiguous quantity. Diet research leans on that quantity more than most, which makes a Mediterranean diet trial that counted heart attacks instead unusual.

What it means practically

  • The cardiovascular benefit is not a reward for losing weight. In SELECT, people who lost less were protected about as much as people who lost more.
  • That is reassuring for slow responders, who often conclude the drug is not working.
  • Waist may be the better thing to watch than weight, and it is the cheaper measurement.
  • Unexplained weight loss without a drug is a reason to see a doctor, not a success.

Two limits belong with all of it. The trial was funded by Novo Nordisk, which makes semaglutide; that is ordinary, and Cochrane’s semaglutide review found most of the drug’s trials were paid for by its manufacturer. And the 33% mediation figure is a modeling estimate that rests on assumptions trial data cannot verify, the same caution that applies to every mediation analysis.

Frequently Asked Questions

Mostly not. In a prespecified analysis of 17,604 SELECT participants, weight lost by week 20 showed no linear relationship with later heart attacks and strokes, and only about a third of the benefit was mediated through waist reduction.
The likeliest reason is that, without a drug causing it, weight loss often signals illness: developing cancer, heart failure, or the decline preceding a cardiac event. In that case the weight loss is a symptom rather than a cause, which epidemiologists call reverse causation.
Because it appeared inside a randomized trial, in the control arm, where it cannot be dismissed as an artifact of observational data. The same measurement in the same trial means opposite things depending on why the weight moved.
For cardiovascular protection, the trial found benefit across every baseline weight and waist category, and no linear relationship between early weight loss and later events. That is reassuring for people who respond slowly.
Waist reduction was the adiposity measure that tracked cardiovascular benefit in this analysis, while weight was not. It also reflects visceral fat rather than lumping fat together with muscle and water.

References

  1. 1.Deanfield J, Lincoff AM, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial The Lancet. 2025. PMID: 41138739.

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.0

YourEra

Semaglutide at $99/month, well below the typical price

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

7.3

Found

People who want clinician visits billed to commercial insurance, with compounded medication in the plan price

From $149/mo + membership

Get started →
Read full review →

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →